Last update 27 Dec 2025

Anti-CD19/BCMA CAR-NK Cells(The Children's Hospital of Zhejiang University School of Medicine)

Overview

Basic Info

Drug Type
CAR-NK
Synonyms
KN-5601
Target
BCMA x CD19
Action
modulators
Mechanism
BCMA modulators(B-cell maturation protein modulators), CD19 modulators(B-lymphocyte antigen CD19 modulators)
Therapeutic Areas
Immune System DiseasesSkin and Musculoskeletal DiseasesUrogenital Diseases+ [1]
Active Indication
Immunoglobulin G4-Related DiseaseGlomerulonephritis, IGALupus Erythematosus, Discoid+ [1]
Inactive Indication-
Originator Organization
The Children's Hospital of Zhejiang University School of Medicine
Active Organization
The Children's Hospital of Zhejiang University School of MedicineChanghai Hospital of Shanghai
Inactive Organization-
License Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with Anti-CD19/BCMA CAR-NK Cells(The Children's Hospital of Zhejiang University School of Medicine)
NCT07298590
/ Not yet recruitingEarly Phase 1IIT
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK (KN5601) in the Treatment of Relapsed and Refractory IgG4-related Disease (IgG4-RD)
NCT07283315
/ RecruitingEarly Phase 1IIT
Exploratory Clinical Study on the Safety and Efficacy of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases
NCT06792799
/ RecruitingEarly Phase 1IIT
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA Chimeric Antigen Receptor NK Cells in the Treatment of B Cell-related Autoimmune Diseases in Children
100 Clinical Results associated with Anti-CD19/BCMA CAR-NK Cells(The Children's Hospital of Zhejiang University School of Medicine)
Login to view more data
100 Translational Medicine associated with Anti-CD19/BCMA CAR-NK Cells(The Children's Hospital of Zhejiang University School of Medicine)
Login to view more data
100 Patents (Medical) associated with Anti-CD19/BCMA CAR-NK Cells(The Children's Hospital of Zhejiang University School of Medicine)
Login to view more data
100 Deals associated with Anti-CD19/BCMA CAR-NK Cells(The Children's Hospital of Zhejiang University School of Medicine)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Immunoglobulin G4-Related DiseasePhase 1
China
Changhai Hospital of Shanghai
30 Dec 2025
Glomerulonephritis, IGAPhase 1
China
The Children's Hospital of Zhejiang University School of Medicine
30 Jan 2025
Lupus Erythematosus, DiscoidPhase 1
China
The Children's Hospital of Zhejiang University School of Medicine
30 Jan 2025
Nephrotic SyndromePhase 1
China
The Children's Hospital of Zhejiang University School of Medicine
30 Jan 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT06792799 (ASN2025)
Phase 1
Systemic Lupus Erythematosus
11
ysyyezcjzp(sfqesaxvkd) = oomojtzeqd rqskocjqri (kushshoury )
Positive
08 Nov 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free